|
1. Lyczak JB, Cannon CL, Pier GB. Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes Infect. 2000 Jul; 2(9): 1051-60. 2. Agodi A, Barchitta M, Cipresso R, Giaquinta L, Romeo MA, Denaro C. Pseudomonas aeruginosa carriage, colonization, and infection in ICU patients. Intensive Care Med. 2007 Jul; 33(7): 1155-61. 3. Navon-Venezia S, Ben-Ami R, Carmeli Y. Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis. 2005 Aug; 18(4): 306-13. 4. Vettoretti L, Floret N, Hocquet D, Dehecq B, Plésiat P, Talon D, et al. Emergence of extensive-drug-resistant Pseudomonas aeruginosa in a French university hospital. Eur J Clin Microbiol Infect Dis. 2009 Oct; 28(10): 1217-22. doi:10.1007/s10096-009-0767-8 5. Sabharwal N, Dhall S, Chhibber S, Harjai K. Molecular detection of virulence genes as markers in Pseudomonas aeruginosa isolated from urinary tract infections. Int J Mol Epidemiol Genet. 2014; 5(3): 125-34. 6. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev. 2009 Oct; 22(4): 582-610. doi:10.1128/CMR.00040-09 7. Lutz JK, Lee J. Prevalence and antimicrobialresistanceof Pseudomonas aeruginosa in swimming pools and hot tubs. Int J Environ Res Public Health. 2011; 8(2): 554-64. doi:10.3390/ijerph8020554 8. Quan F, Liu G, Wang L, Wang X. Investigation of pulmonary infection pathogens in neurological intensive care unit. Ther Clin Risk Manag. 2011; 7: 21-5. doi:10.2147/TCRM.S15730 9. Wiehlmann L, Wagner G, Cramer N, Siebert B, Gudowius P, Morales G, et al. Population structure of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 2007; 104(9): 8101-6. doi:10.1073/pnas.0609213104 10. Murray RGE, Holt JG, Krieg NR, Sneath PHA. Bergey’s manual of systematic bacteriology. 1st ed. Baltimore: Williams and Wilkins. 2001; pp: 141-219. 11. López DJ, Collado MI, Ibarguren M, Vasil AI, Vasil ML, Goñi FM, et al. Multiple phospholipid substrates of phospholipase C/sphingomyelinase HR2 from Pseudomonas aeruginosa. Chem Phys Lipids. 2011 Jan; 164(1): 78-82. doi:10.1016/j.chemphyslip.2010.11.001 12. Ostroff RM, Vasil AI, Vasil ML. Molecular comparison of a nonhemolytic and a hemolytic phospholipase C from Pseudomonas aeruginosa. J Bacteriol. 1990 Oct; 172(1): 5915-23. 13. Mattick JS. Type IV pili and twitching motility. Annu Rev Microbiol. 2002; 56: 289-314. doi:10.1146/annurev.micro.56.012302.160938 14. Maschmeyer G, Braveny I. Review of the incidence and prognosis of Pseudomonas aeruginosa infections in cancer patients in the 1990s. Eur J Clin Microbiol Infect Dis. 2000 Dec; 19(12): 915-25. 15. Lee KK, Sheth HB, Wong WY, Sherburne R, Paranchych W, Hodges RS, et al. The binding of Pseudomonas aeruginosa pili to glycosphingolipids is a tip-associated event involving the C-terminal region of the structural pilin subunit. Mol Microbiol. 1994 Feb; 11(4): 705-13. 16. Graupner S, Frey V, Hashemi R, Lorenz MG, Brandes G, Wackernagel W. Type IV pilus genes pilA and pilC of Pseudomonas stutzeri are required for natural genetic transformation, and pilA can be replaced by corresponding genes from nontransformable species. J Bacteriol. 2000 Apr; 182(8): 2184-90. 17. Clinical an Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 23th Informational Supplement. CLSI document M100-S25. 2015; Vol 35. No 3. 18. Mahmood Ra'oof W. Distribution of algD, lasB, pilB and nan1 genes among MDR clinical isolates of Pseudomonas aeruginosa in respect to site of infection. Medical Journal of Tikrit. 2011; 17(2): 148-60. 19. Jamali S, Shahid M, Farrukh S, Singh A, M. Khan HM. Molecular characterization of genes encoding AmpC beta-lactamases in clinical isolates of Pseudomonas and Acinetobacter species. J App Pharm Sci. 2015; 5(10): 48-51. doi:10.7324/JAPS.2015.501009 20. Fazeli H, Havaei SA, Solgi H, Shokri D, Motallebirad T. Pattern of Antibiotic Resistancein Pesudomonas Aeruginosa Isolated from Intensive Care Unit, Isfahan, Iran. J Isfahan Med Sch. 2013; 31(232): 433-38. 21. Finnan Sh, Morrissey JP, O’Gara F, Boyd F. Genome Diversity of Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients and the Hospital Environment. J Clin Microbiol. 2004; 42(12): 5783-92. doi:10.1128/JCM.42.12.5783-5792.2004 22. Wolska K, Szweda P. Genetic features of clinical Pseudomonas aeruginosa strains. Pol J Microbiol. 2009; 58(3): 255-60. 23. Ugargol AR, Srikanth NS, Shilpa K, Santosh Patil. Characterisation and Detection of Virulence Factors, Alginate and Phospholipase ‘C’ in Pseudomonas Aeruginosa in a Tertiary Care Hospital. Int J Health Sci Res. 2014; 4(5): 82-87. 24. Mitov I, Strateva T, Markova B. Prevalence of Virulence Genes Among Bulgarian Nosocomail And Cystic Fibrosis Isolates of Pseudomonas aeruginosa. Braz J Microbiol. 2010; 41(3): 588–95. doi:10.1590/S1517-83822010000300008 25. Sonbol FI, Khalil MA, Mohamed AB, Ali SS. Correlation between antibiotic resistance and virulence of Pseudomonas aeruginosa clinical isolates. Turk J Med Sci. 2015;45(3):568-77. 26. Fazeli N, Momtaz H. Virulence Gene Profiles of Multidrug-Resistant Pseudomonas aeruginosa Isolated From Iranian Hospital Infections. Iran Red Crescent Med J. 2014 Oct; 16(10): e15722. doi:10.5812/ircmj.15722 27. Salimi Chirani A, Dabiri H, Nikokar I, Ebrahimpour Komleh M, Dousdar F, Goudarzi H, et al. [Evaluation of type IV pilin sub groups in Pseudomonas aeruginosa isolated from environmental samples, cystic fibrosis and burn patients]. Iran J Med Microbiol. 2014; 8(3): 1-7. [Article in Persian]
|
